| Biomarker ID | 52 |
| PMID | 15609297 |
| Year | 2005 |
| Biomarker | GalNAc-T3+Hepsin+DD3 |
| Biomarker Basis | Expression Based |
| Biomolecule | mRNA |
| Source | Tissue |
| Subjects | Humans |
| Regulation | Upregulated in PCa |
| Odds Ratio/Hazard Ratio/Relative Risk | NA |
| Effect on Pathways | Pathways Include(GALNT3):-O-glycan biosynthesis,O-linked glycosylation of mucins, Post-translational protein modif,Protein met,Interleukin-2 signaling pathwayabolismication |
| Experiment | Prostate Cancer Vs benign prostatic hyperplasia |
| Type of Biomarker | Diagnostic |
| Cohort | 18 patients with prostate cancer and 34 patients woth Benign Prostatic Hyperplasia (BPH) were tested against these 4 biomarkers to see how easily these 2 groups could be distinguished from one another |
| Senstivity | BPH Prediction: 97.1% |
| Specificity | PCA Prediction: 94.4% |
| AUC | NA |
| Accuracy | 96.2% |
| Level Of Significance | NA |
| Method Used | RT-PCR |
| Clinical | No |
| Remarks | The ratios of gene expression/10^5 copies of β2-microglobulin were calculated, in samples of PCa and BPH tissues |
| Clinical Trial Number | NA |
| Degree Of Validity | Not validated on independent patient dataset |
| Technical Name | GALNT3, Hepsin, PCA3 |